Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

'Click' chemistry shows promise for canine bone cancer
X-ray image of swelling forelimb lameness dog show osteosarcoma bone tumour at foreleg.

Researchers have successfully used the Nobel-winning process in large dogs. 

A Nobel Prize-winning science known as 'click' chemistry could help treat treat dogs with bone cancer, according to new research.

Discovered by scientists from California and Denmark, click chemistry is a process whereby molecules snap together like LEGO, making them more effective at delivering drugs to treat tumours.

Until recently, the process had only been successful in small mice, but a new study by the University of Missouri has shown for the first time how it could treat large dogs, and potentially humans, with osteosarcoma.

Jeffrey Bryan, a professor at the MU College of Veterinary Medicine and author of the study, said: “If you want to attack a tumour using the immune system, an antibody is an extremely specific way to deliver a drug or radioactive payload to the tumour, but the problem with antibodies is they are huge molecules that circulate in the bloodstream for days or even weeks.

“If you put a drug or radioactive molecule onto the antibody, you leave radioactivity circulating in the bloodstream for a long time, which can spread to and negatively impact organs, bone marrow and the liver while not getting as much dose to the specific tumour as you were hoping for.”

Click chemistry aims to maximise the delivery of drugs to the tumour while minimising their circulation in the bloodstream and causing harmful side effects. It has long been assumed that the process would not work in large dogs or people because the body may be too big for the molecules to find each other and 'click' together.

In this research, scientists at MU College of Veterinary Medicine carried out a 'proof-of-concept' study whereby they used the method to deliver doses of radiopharmaceuticals to treat tumours in five dogs weighing more than 100 pounds.

Study author Brian Zeglis, associated professor at Hunter College, New York, described their finding as “a huge step forward for the field”, adding that it could “pave the way for click chemistry to be used to help humans with cancer in the future”.

“Osteosarcoma, a common form of bone cancer, impacts both dogs and people, and it causes severe pain, limping, swelling in the limbs, and treating the bone tumours with various radiation therapy and immune therapy approaches to take away the pain is something I am passionate about here at MU," he said.

Everything we learn about treating these dogs can be translated to help humans down the road.”

The study, “Pretargeted PET of Osteodestructive Lesions in Dogs” is published in Molecular Pharmaceutic.

Image (C) Shutterstock.

Become a member or log in to add this story to your CPD history

Strangles survey seeks views of horse owners

News Story 1
 With Strangles Awareness Week just around the corner (5-11 May), vets are being encouraged to share a survey about the disease with their horse-owning clients.

The survey, which has been designed by Dechra, aims to raise awareness of Strangles and promote best practices to prevent its transmission. It includes questions about horse owners' experiences of strangles, together with preventative measures and vaccination.

Respondents to the survey will be entered into a prize draw to win two VIP tickets to Your Horse Live 2025. To access the survey, click here 

Click here for more...
News Shorts
Vivienne Mackinnon elected BVA Scottish Branch President

The British Veterinary Association (BVA) has elected Vivienne Mackinnon as its new BVA Scottish Branch president.

Dr Mackinnon has over 30 years of experience in veterinary care, encompassing both small animal and mixed practice. She has worked in practices in Scotland, England, New Zealand and Australia, before joining APHA to work in frontline disease control.

In her speech, Dr Mackinnon reflected on the changes in Scotland's veterinary industry and highlighted her commitment to veterinary education.

Dr Mackinnon said: "I look forward to working with colleagues across the veterinary professions to improve animal health and welfare in the country and support veterinary workplaces."